About the book
Atopic dermatitis is one of the most frequent skin disorders, particularly in pediatric ages. The enormous heterogeneity of mechanisms, triggers, clinical severity patterns, and treatment strategies have allowed a huge set of data from recent research that will allow more personalized management of the disease. Several clinical phenotypes were identified and engaged on precise pathogenic mechanisms whereby different cells and mediators are critical representing current discussion hot topics. An example is non-histaminergic pruritus with enormous difficulties in the clinic and with obvious implications on patient’s daily quality of life. Since skin barrier dysfunction is a very important aspect in the pathogenesis, the new investigations with emollient and humectants agents are very promising because they will allow more careful prescriptions directed to different clinical patterns. In addition to the standard pharmacological therapeutic, new topical or systemic agents, anti-inflammatory, immunomodulatory or biological agents, are now undergoing clinical trials with very promising results, despite the inexistent of clinical robust biomarkers. Similarly, in clinical phenotypes with outbreaks of recurrent skin infection by bacteria or fungi, future investigations with agents capable of destroying biofilms may have excellent benefit in the patient’s management. This book project will aim to frame the most current phytopathogenic evidence in atopic dermatitis and the scientific rationale of the currently available therapeutic arsenal and the new options that are projected particularly for severe forms of the disease.